ASCO GI Symposium 2024: Focus on Liver Cancer
Stay up-to-date with the latest research and clinical updates on liver cancer from the 2024 ASCO GI Symposium.
In patients with HCC, a high CD8 and low TIM3 expression is linked to better OS than PD-1/PD-L1.
Dr. Elizabeth Conner offers insight on how DCP can be utilized as a biomarker for treatment response in patients with HCC.
Dr. Brown discussed the results of a retrospective analysis on the addition of radiation to atezolizumab and bevacizumab.
Durvalumab plus bevacizumab with TACE demonstrated significantly improved PFS rates over TACE monotherapy.
A new report detailed the results of the LEAP-002 study following 12 months of additional follow-up.
In 35 patients, the Eastern Cooperative Oncology Group performance status (ECOG-PS) was 0.
An analysis of demographic, clinical characteristics, and treatment patterns for HCC for defining early-stage disease.
A retrospective review offers insights into the safety and efficacy of adding CDDP to lenvatinib for patients with aHCC.
Of the 1115 patients, 83.2% were male, 49.1% were current or ex-smokers, and 21.4% had consumed alcohol.
Comparing the efficacy of atezo/beva for patients with aHCC who were previously treated with lenva versus no prior treatment.
Advertisement
Advertisement
